One of the world leading research and advisory firm for pharmaceutical and healthcare issues.

Almost half of surveyed urologists Show Approval of Provenge as a breakthrough in the treatment of prostateDecision Resources, one of the world leading research and advisory firm for pharmaceutical and healthcare issues, states that see nearly half of surveyed urologists the approval of the Dendreon Provenge as a breakthrough in the treatment of prostate cancer, compared with 31 % of the surveyed oncologist. However, the agent writes oncologists often than urologists. 12 months after doctors questioned 15 % 15 % with with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer received Provenge, despite the views of many physicians surveyed, that the launch of Provenge, a breakthrough in the stands , the treatment of prostate.

In November Alzheimer’s Disease Awareness MonthTwenty five years ago was designated as was designated as National Alzheimer’s Disease Awareness Month. At the time, less than 2 Alzheimer’s Alzheimer’s. Today, many are surviving from 5.2 million Americans with Alzheimer’s disease – 120,000 of which are in Massachusetts. Alzheimer’s can occur as young as 35 years old, and currently is the sixth leading cause of death in the country. 2050 11 to 16,000 people are likely Alzheimer. – Although there is much we do not yet Alzheimer’s disease Alzheimer’s disease, enormous progress has been made since 1983, said James Wessler, President and CEO of the Alzheimer’s Association MA / NH Chapter. In November, we focus on raising awareness of Alzheimer’s disease and shed light on the importance of finding breakthroughs in diagnosis, prevention, treatment and eventually a cure.The worldwide prevalence for neuropathic pain is thought that at least 2.4 % and longer than 55 years ago at which be. Diabetic neuropathies are a family of illnesses of the nervous system ischemia reperfusion injury to diabetic by numbness, weakness and often cause pain in the hands, feet and legs. On 15 %age of people with diabetes in the U.S. is intended diabetic diabetic nerve pain. Market for of neuropathic pain treatments estimated at approximately USD 2.5 billion and growth.. On neuropathicneuropathic pain may to be due caused by nerve injury the often difficult to treat and not react for the treatments active other types of aches.

Over TrophosTrophos is a biopharmaceutical company that is handle on discover and develop of novel therapeutic agents to treat neurological disorders and other conditions with high unmet medical need. Which Trophos detection strategy facilitated is of developing a portfolio from proprietary products, such as its lead product TRO19622 and drug candidates TRO40303 that grant a survival benefit according underlined neuronal and non – neuronal cell types ..